

# Takafumi Koyama

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/386590/publications.pdf>

Version: 2024-02-01

9  
papers

366  
citations

1478505

6  
h-index

1474206

9  
g-index

9  
all docs

9  
docs citations

9  
times ranked

446  
citing authors

#	ARTICLE	IF	CITATIONS
1	Feasibility and utility of a panel testing for 114 cancer-associated genes in a clinical setting: A hospital-based study. <i>Cancer Science</i> , 2019, 110, 1480-1490.	3.9	238
2	First-in-Human Phase 1 Study of MORAb-202, an Antibody-Drug Conjugate Comprising Farletuzumab Linked to Eribulin Mesylate, in Patients with Folate Receptor-1-Positive Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2021, 27, 3905-3915.	7.0	37
3	Safety and pharmacokinetics of milademetan, a MDM2 inhibitor, in Japanese patients with solid tumors: A phase I study. <i>Cancer Science</i> , 2021, 112, 2361-2370.	3.9	33
4	Phase I/IIa Trial of BMS-986148, an Anti-mesothelin Antibody-drug Conjugate, Alone or in Combination with Nivolumab in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2022, 28, 95-105.	7.0	24
5	First-in-human phase I study of E7090, a novel selective fibroblast growth factor receptor inhibitor, in patients with advanced solid tumors. <i>Cancer Science</i> , 2020, 111, 571-579.	3.9	16
6	First-in-human study of the cancer peptide vaccine TAS0313 in patients with advanced solid tumors. <i>Cancer Science</i> , 2021, 112, 1514-1523.	3.9	6
7	Study protocol for NCCH1908 (UPFRONT-trial): a prospective clinical trial to evaluate the feasibility and utility of comprehensive genomic profiling prior to the initial systemic treatment in advanced solid tumour patients. <i>Japanese Journal of Clinical Oncology</i> , 2021, 51, 1757-1760.	1.3	5
8	Merestinib monotherapy or in combination for Japanese patients with advanced and/or metastatic cancer: A phase 1 study. <i>Cancer Medicine</i> , 2021, 10, 6579-6589.	2.8	4
9	Dose Escalation Data from the Phase 1 Study of the Liposomal Formulation of Eribulin (E7389-LF) in Japanese Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2022, 28, 1783-1791.	7.0	3